![](https://www.pharmavoice.com/imgproxy/mPUZErnwKHx4VQ7mLGQzhsDidn8CO3Mx5t_zz-XLHvo/g:nowe:0:388/c:5567:3145/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTE0ODEwNTc2NDQuanBn.webp)
As the GLP-1 market booms, other healthcare companies are cashing in
The popularity of weight loss drugs is giving rise to a secondary market with big earning potential, and companies are clamoring for a piece of the action. Obesity treatments from Novo Nordisk and Eli Lilly are poised to become some of the most popular …